We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

78 hedge funds and large institutions have $460M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

11% less funds holding

Funds holding: 8878 (-10)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

40% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 25

44% less capital invested

Capital invested by funds: $822M → $460M (-$363M)

Holders
78
Holders Change
-10
Holders Change %
-11.36%
% of All Funds
1.74%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
15
Increased
31
Reduced
19
Closed
25
Calls
$243K
Puts
Net Calls
+$243K
Net Calls Change
-$109K
Name Holding Trade Value Shares
Change
Change in
Stake
NLVP
1
New Leaf Venture Partners
New York
$86.1M
O
2
OrbiMed
New York
$51.3M +$12M +488,700 +25%
RG
3
Redmile Group
California
$34.7M +$4.34M +176,600 +12%
SHI
4
SV Health Investors
Massachusetts
$27M -$10.5M -429,076 -25%
Millennium Management
5
Millennium Management
New York
$26.2M +$28.6M +1,163,815 +1,405%
BlackRock
6
BlackRock
New York
$24.6M +$12.2M +497,427 +74%
Vanguard Group
7
Vanguard Group
Pennsylvania
$15M +$925K +37,645 +6%
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$14.7M +$565K +22,998 +3%
EA
9
Emerald Advisers
Pennsylvania
$13.1M -$2.01M -81,610 -12%
AllianceBernstein
10
AllianceBernstein
Tennessee
$13M +$858K +34,901 +6%
EMFAT
11
Emerald Mutual Fund Advisers Trust
Pennsylvania
$12.9M -$1.33M -53,981 -8%
DM
12
Deerfield Management
New York
$12.8M +$14.9M +607,633 New
State Street
13
State Street
Massachusetts
$12.4M +$78.5K +3,193 +0.5%
Citadel Advisors
14
Citadel Advisors
Florida
$11.3M +$5.46M +221,981 +70%
Alkeon Capital Management
15
Alkeon Capital Management
New York
$10.5M +$3.04M +123,547 +33%
ACH
16
ArrowMark Colorado Holdings
Colorado
$7.47M +$614K +24,967 +8%
OM
17
Opaleye Management
Massachusetts
$7.14M -$1.97M -80,000 -19%
Norges Bank
18
Norges Bank
Norway
$6.97M -$4.12M -167,739 -34%
Point72 Asset Management
19
Point72 Asset Management
Connecticut
$6.3M +$7.38M +300,000 New
SI
20
Sofinnova Investments
California
$5.57M +$6.53M +265,475 New
Lord, Abbett & Co
21
Lord, Abbett & Co
New Jersey
$4.97M -$3.08M -125,417 -35%
KCM
22
Kornitzer Capital Management
Kansas
$4.49M +$625K +25,410 +13%
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$4.34M +$5.08M +206,615 New
DCM
24
Driehaus Capital Management
Illinois
$3.82M -$1.5M -60,923 -25%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$3.5M +$668K +27,157 +19%

DCPH Hedge Fund Activity: Q4 2018 in Review

78 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2018, worth a combined $460M — down 44% from $822M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of DCPH and 15 opened new positions — a net loss of 10 holders — while 19 trimmed existing stakes and 31 added.

The largest buyer was Millennium Management, adding an estimated $28.6M. The largest seller was Polar Capital, exiting entirely with an estimated $31.2M sold.

  • 78 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2018, down from 88 in Q3 2018.
  • Funds reported $460M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2018, down 44% quarter-over-quarter.
  • 15 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 25 closed out, a net change of -10 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was Millennium Management, an estimated $28.6M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2018 was Polar Capital, an estimated $31.2M sold.

Based on aggregated 13F filings for Q4 2018.